We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives
- Indications for anticoagulation
- Incidence of Venous Thromboembolism (VTE)
- DVT/PE consequences
- VTE Treatment
- Anticoagulant Classes
- Coagulation Cascade
- ‘Natural’ anticoagulants
- Heparin
- Heparin: mechanism of action
- Heparin: generalities
- Low Molecular Weight Heparin (LMWH)
- LMWH: mechanism of action
- LMWH: generalities
- Direct Thrombin Inhibitors (DTIs)
- DTIs: generalities
- Warfarin, vitamin K antagonist
- Warfarin: generalities
- Warfarin: dosing & monitoring
- Direct Oral Anticoagulants (DOACs)
- DOACs: dosing for VTE
- DOACs: dosing & monitoring
- Duration of VTE treatment
- Provoked VTE: factors & duration
- Provoked VTE: treatment model
- Unprovoked VTE: duration
- Unprovoked VTE: treatment model
- ‘Long-term’ anticoagulation
- Objectives & summary
- Thank you
Topics Covered
- Indications for anticoagulation
- Venous thromboembolism (VTE): incidence, treatment, and duration
- ‘Natural’ anticoagulants
- Heparin
- Low molecular weight heparin
- Direct thrombin inhibitors
- Warfarin
- Direct oral anticoagulants
- Provoked VTE
- Unprovoked VTE
Links
Categories:
Therapeutic Areas:
Talk Citation
Pishko, A. (2023, January 31). Anticoagulation for venous thromboembolism [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/BSTT8989.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Allyson Pishko has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Physiology & Anatomy
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone,
I'm Allyson Pishko
from the University
of Pennsylvania,
and I'll be presenting
on anticoagulation
for venous thromboembolism.
0:10
The objectives for
today's talk will be to
review the indications
for anticoagulation,
then we will focus on a
specific indication for
anticoagulation -
venous thromboembolism.
We'll describe the phases of
treatment of venous thromboembolism,
then go on to describe
the mechanisms of
different anticoagulants.
We will then develop a framework
for determining the duration
of anticoagulation for
the treatment of venous
thromboembolism.
0:39
Anticoagulants are
popular medications as
there are many indications
for anticoagulation.
This includes prevention
or primary prophylaxis,
which is stroke prevention
and patients at high risk
due to atrial fibrillation.
It can be used for deep
vein thrombosis prophylaxis
in high-risk patients such as
hospitalized patients or
patients undergoing surgery.
It is also a medication that
is used in the treatment of
acute DVT or pulmonary embolism,
and also used in peripheral
arterial disease.
Anticoagulants can
also be used for
secondary prophylaxis, such as
the prevention of recurrent VTE
or recurrent stroke.
This talk will focus on
acute DVT or
pulmonary embolism treatment
with anticoagulants.
1:28
This is an important problem
as venous thromboembolism,
which includes pulmonary
embolism and DVT,
occurs commonly in
the population.
There are over 10
million cases of
VTE diagnosed
annually worldwide.